BofA/Merrill Lynch Upgrades Acadia Pharmaceuticals (ACAD) to Buy
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $16.74 -1.47%
Rating Summary:
14 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Rating Summary:
14 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Join SI Premium – FREE
BofA/Merrill Lynch upgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Neutral to Buy with a price target of $35.00.
For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.
Shares of Acadia Pharmaceuticals closed at $22.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acadia Pharma (ACAD) Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
- JPMorgan Upgrades Assai Atacadista (ASAI) to Overweight
- Janney Upgrades Sierra Bancorp (BSRR) to Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
